GBIM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (14 Mar 2024 @ 14:43):

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform...

Stats
Today's Volume	756.00
Average Volume	0.00
Market Cap	10 065.00
EPS	$-0.150 ( 2016-05-12 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2016-03-16	Mitchell Daniel J	Sell	8 862	Common Stock
2016-03-17	Mitchell Daniel J	Sell	12 468	Common Stock
2016-03-16	Mitchell Daniel J	Sell	112	Common Stock
2016-03-17	Mitchell Daniel J	Sell	158	Common Stock
2016-03-11	Mitchell Daniel J	Sell	76 662	Common Stock

INSIDER POWER
0.00
Last 99 transactions
Buy: 1 518 952 \| Sell: 29 605 418

Volume Correlation

Long: -0.32 (neutral)

Short: 0.21 (neutral)

Signal:(24.043) Neutral

GlobeImmune, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GlobeImmune, Inc. Correlation - Currency/Commodity

0.00
( neutral )

GlobeImmune, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

Q1	2016
Revenue:	$942 750
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.150

Q4	2015
Revenue:	$1.05M
Gross Profit:	$1.05M (100.00 %)
EPS:	$-0.138

Q3	2015
Revenue:	$2.94M
Gross Profit:	$2.94M (100.00 %)
EPS:	$0.160

Financial Reports:

No articles found.

GlobeImmune, Inc.

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.